Showing 4121-4130 of 9407 results for "".
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- BE BOLD: Bimekizumab Shows Superiority Over IL-23 Inhibitor in Psoriatic Arthritishttps://practicaldermatology.com/news/be-bold-trial-bimekizumab-shows-superiority-over-il-23-inhibitor-in-psoriatic-arthritis/2486038/Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity at Week 16 in adults with active psoriatic arthritis (PsA), according to topline results from the phase 3 BE BOLD head-to-head trial announced by UCB.
- Review: Gut Microbiota Dysbiosis Linked With AD, Psoriasis, and HShttps://practicaldermatology.com/news/review-gut-microbiota-linked-with-dysbiosis-with-ad-psoriasis-and-hs/2485997/A new systematic review suggests that alterations in gut microbial composition may contribute to atopic dermatitis (AD), psoriasis, and hidradeni
- Oral Melatonin Shows Benefits for Pruritus, Sleep, and QoL in ADhttps://practicaldermatology.com/news/oral-melatonin-shows-benefits-for-pruritus-sleep-and-qol-in-ad/2485982/Melatonin supplementation significantly improved disease severity and several patient-reported outcomes in adults with mild to moderate atopic de
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Analysis: Tapinarof Cream Yields Improved Sleep in Pediatric ADhttps://practicaldermatology.com/news/analysis-links-tapinarof-cream-to-early-sleep-improvements-in-pediatric-ad/2485802/A new analysis of the phase 3 ADORING 1 and ADORING 2 trials showed that tapinarof cream, 1% (VTAMA, Organon) was associated with early and sustained improvements in sleep-related patient-reported outcomes in pediatric patients with moderate to severe atopic derma
- Hair Prosthetic Injuries Disproportionately Affect Women in US Emergency Departmentshttps://practicaldermatology.com/news/hair-prosthetic-injuries-disproportionately-affect-women-in-us-emergency-departments/2485826/A recent analysis of the National Electronic Injury Surveillance System (NEISS) looking at hair prosthetic–related injuries presenting to US emergency departments (EDs) between 2013 and 2022 suggested these injuries disproportionately affect women.
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin